Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06027099 · ClinicalTrials.gov registry record · Phase 3
CARES-Spine (Comprehensive Analgesic, Recovery, and Education Support for Spine Surgery) Trial
A Phase 3 study of Chronic Pain and Back Pain, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 375
- Enrollment target
- 1
- Study location
NCT06027099: Recruiting Phase 3 study of Chronic Pain and Back Pain, sponsored by Stanford University.
NCT06027099 is a Phase 3 study of Chronic Pain and Back Pain that is actively recruiting participants, run by Stanford University. The registered enrollment target is 375 participants, below the 771-participant average among 301 other Chronic Pain trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06027099, a Phase 3 study of Chronic Pain and Back Pain, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 375 participants
- Enrollment target
- 1
- Study location
Study Summary
Three-arm randomized controlled trial, of Motivational Interviewing and guided Opioid Tapering support (MI-Opioid Taper) and tizanidine vs. MI-Opioid Taper and placebo vs. enhanced usual care to promote postoperative opioid cessation and pain cessation and reduce the incidence of postoperative opioid misuse among patients undergoing spine surgery.
Primary Outcome
Defined as the first of two consecutive reports of return to preoperative daily MME or lower on the modified Brief Pain Inventory (mBPI) or the Recent Opioid Medication Use survey. Preoperative daily MME use is defined as average daily MME assessed during the Preoperative Call in the 1-5 day window prior to surgery.
Conditions Studied
Interventions
- DRUG Placebo
- BEHAVIORAL Enhanced Usual Care
- DRUG Tizanidine
- BEHAVIORAL MI-Opioid Taper
Study Locations (1)
California
- Stanford University Hospital - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2024-12-05 |
| Est. Completion | 2028-07 |
| Phase | Phase 3 |
What NCT06027099 shows while recruiting
NCT06027099 is an interventional study that assigns participants to a tested intervention. The registered 375 participants enrollment target is mid-sized for trials with a published cap, below the 771-participant average among 301 other Chronic Pain trials with a reported enrollment target (51% lower).
The record links to 4 conditions, with Chronic Pain appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT06027099 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06027099 about?
NCT06027099 is a clinical study titled "CARES-Spine (Comprehensive Analgesic, Recovery, and Education Support for Spine Surgery) Trial". Three-arm randomized controlled trial, of Motivational Interviewing and guided Opioid Tapering support (MI-Opioid Taper) and tizanidine vs. MI-Opioid Taper and placebo vs. enhanced usual care to promote postoperative opioid cessation and pain cessation and reduce the incidence of postoperative opioi...
What is the current status of trial NCT06027099?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 375 participants. The study started on 2024-12-05. Estimated completion is 2028-07.
What conditions does trial NCT06027099 study?
This clinical trial studies the following conditions: Chronic Pain, Back Pain, Neck Pain, Opioid Misuse.
What interventions are being tested in trial NCT06027099?
The interventions under investigation include: Placebo (DRUG), Enhanced Usual Care (BEHAVIORAL), Tizanidine (DRUG), MI-Opioid Taper (BEHAVIORAL).
Who is sponsoring clinical trial NCT06027099?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06027099 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06027099's enrollment target sits among peer trials
375 38th of 301 higher than 264 of 301 other Chronic Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tele-Collaborative Outreach to Rural Patients With Chronic Pain
RECRUITING · Phase 3
-
Nonpharmacologic Pain Management in FQHC Primary Care Clinics
RECRUITING · Phase 3
-
Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits
RECRUITING · Phase 3
-
Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant Pain
COMPLETED · Phase 3
-
Digital Therapeutic for Chronic Pain Feasibility Study
COMPLETED · Phase 3
-
An Implantable Spinal Cord Stimulation Pain Management System
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03686124 · 375 participants · Phase 1
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- NCT04059172 · 375 participants · Early Phase 1
Efficacy of Combined Ibuprofen and Acetaminophen Therapy Versus Ibuprofen Alone Versus Placebo Alone for Pain Management
- NCT04134923 · 375 participants
Imaging Biomarkers in Preclinical and Symptomatic AD
- NCT04569747 · 375 participants · Phase 2
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI